Allovir Inc Company Overview
About Allovir Inc
Allovir (NASDAQ:ALVR) focuses on developing innovative therapies to tackle viral diseases, particularly in immunocompromised patients. The company is traded on NASDAQ under the ticker symbol ALVR. It specializes in creating cell therapies designed to restore natural immunity against devastating viral infections. Some of its key projects include groundbreaking treatments for viruses like BK, cytomegalovirus, and adenovirus, designed to enhance the immune response of transplant patients. Allovir's objectives revolve around advancing its pipeline of investigational therapies through rigorous clinical trials and receiving regulatory approvals to bring these life-saving treatments to market. By translating significant scientific breakthroughs into practical healthcare solutions, Allovir aims to address urgent unmet medical needs and improve patient outcomes globally.
Snapshot
Operations
Products and/or services of Allovir Inc
- Viralym-M: A multi-virus specific T-cell therapy developed to target and treat a range of viral infections, primarily in immunocompromised patients, with strong clinical trial progress.
- ALVR106: An investigational T-cell therapy focused on combatting respiratory viral infections, potentially benefiting patients with conditions like RSV and human rhinovirus.
- ALVR105: A preclinical program aimed at developing a treatment solution for hepatitis B virus infection, leveraging innovative T-cell therapeutic approaches.
- Immunocompromised patient therapies: Comprehensive focus on therapies to address the unique challenges faced by patients with weakened immune systems.
- Partnerships and collaborations: Strategic alliances with academic, clinical, and industrial partners to enhance development and delivery of robust viral infection treatments.
- Clinical trials: Ongoing research and development via clinical trials to continually refine and validate their T-cell therapy offerings for greater efficacy and safety.
Allovir Inc executive team
- Mr. David L. HallalExecutive Chairman of the Board
- Mr. Vikas Sinha C.A., CPA, M.B.A.CEO, President, CFO & Director
- Mr. Brett R. HagenChief Accounting Officer
- Mr. Edward Miller J.D.General Counsel & Secretary
- Dr. Ann M. Leen Ph.D.Chief Scientific Officer